The populations of wealthy western nations are getting older and sicker, while emerging countries are demanding better ...

Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor, sending its shares up 25% in morning trade.

The tragedy of rare disease is not only measured in lives lost—it’s also measured in lives that could have been saved, if only abandoned discoveries had been given another chance.

Immunome’s investigational oral therapy has slashed the risk of disease progression or death by 84% for patients with desmoid ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of ...

Policy swings have made it a slippery year for pharma ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

Europe's universities and research institutes are particularly strong in biotech and pharmaceutical startups. A report from Dealroom shows that since 2022 there have been 244 academic spinouts in ...

Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor, sending its shares up 34.3% in premarket trading. The once-daily oral drug ...

FRANKFURT (Reuters) -Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused on Parkinson's and related diseases that is potentially ...

Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 4.1% in the afternoon session after Wells Fargo upgraded the stock to "Overweight" from "Equal-Weight," citing confidence in the company ...

Merck's newest acquisition grants it access to a highly promising medicine. That could help it overcome the challenges its two biggest franchises are facing. Merck has other things going its way, ...